BRIEF-AzurRx Biopharma To Buy First Wave Bio And Its Proprietary Niclosamide Formulations

Reuters

Sep 13, 2021

Sept 13 (Reuters) - AzurRx BioPharma Inc :

* AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS

* AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED "FIRST WAVE BIOPHARMA" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, "FWBI"

* AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS

* AZURRX BIOPHARMA INC - ENTERED A DEFINITIVE AGREEMENT TO ACQUIRE FIRST WAVE BIO INC IN STOCK AND CASH TRANSACTION VALUED AT $229 MILLION

* AZURRX BIOPHARMA INC - TRANSACTION IS BEING EFFECTED VIA A REVERSE TRIANGULAR MERGER

* AZURRX BIOPHARMA INC - AZURRX'S MANAGEMENT TEAM, INCLUDING JAMES SAPIRSTEIN, WILL CONTINUE TO LEAD RENAMED COMPANY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2167585080"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2167585080\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2167585080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-13 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2167585080","market":"us","top_or_hot":-1,"title":"BRIEF-AzurRx Biopharma To Buy First Wave Bio And Its Proprietary Niclosamide Formulations","media":"Reuters","content":"<html><body><p>Sept 13 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS</p><p>   * AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED \"FIRST WAVE BIOPHARMA\" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, \"FWBI\"</p><p>   * AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS</p><p>   * AZURRX BIOPHARMA INC - ENTERED A DEFINITIVE AGREEMENT TO ACQUIRE FIRST WAVE BIO INC IN STOCK AND CASH TRANSACTION VALUED AT $229 MILLION</p><p>   * AZURRX BIOPHARMA INC - TRANSACTION IS BEING EFFECTED VIA A REVERSE TRIANGULAR MERGER</p><p>   * AZURRX BIOPHARMA INC - AZURRX'S MANAGEMENT TEAM, INCLUDING JAMES SAPIRSTEIN, WILL CONTINUE TO LEAD RENAMED COMPANY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-AzurRx Biopharma To Buy First Wave Bio And Its Proprietary Niclosamide Formulations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-AzurRx Biopharma To Buy First Wave Bio And Its Proprietary Niclosamide Formulations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-13 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Sept 13 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS</p><p>   * AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED \"FIRST WAVE BIOPHARMA\" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, \"FWBI\"</p><p>   * AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS</p><p>   * AZURRX BIOPHARMA INC - ENTERED A DEFINITIVE AGREEMENT TO ACQUIRE FIRST WAVE BIO INC IN STOCK AND CASH TRANSACTION VALUED AT $229 MILLION</p><p>   * AZURRX BIOPHARMA INC - TRANSACTION IS BEING EFFECTED VIA A REVERSE TRIANGULAR MERGER</p><p>   * AZURRX BIOPHARMA INC - AZURRX'S MANAGEMENT TEAM, INCLUDING JAMES SAPIRSTEIN, WILL CONTINUE TO LEAD RENAMED COMPANY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONTF","symbol_name":"ON24, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2167585080","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167585080","pubTimestamp":1631533421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 13  - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS   * AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED \"FIRST WAVE BIOPHARMA\" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, \"FWBI\"   * AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS   * AZURRX BIOPHARMA INC ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONTF":"ON24, Inc."},"translate_title":"简介-Azurrx Biopharma购买第一波生物及其专有氯硝柳胺制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9,"ONTF":0.9},"content_text":"Sept 13 (Reuters) - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS   * AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED \"FIRST WAVE BIOPHARMA\" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, \"FWBI\"   * AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS   * AZURRX BIOPHARMA INC - ENTERED A DEFINITIVE AGREEMENT TO ACQUIRE FIRST WAVE BIO INC IN STOCK AND CASH TRANSACTION VALUED AT $229 MILLION   * AZURRX BIOPHARMA INC - TRANSACTION IS BEING EFFECTED VIA A REVERSE TRIANGULAR MERGER   * AZURRX BIOPHARMA INC - AZURRX'S MANAGEMENT TEAM, INCLUDING JAMES SAPIRSTEIN, WILL CONTINUE TO LEAD RENAMED COMPANYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}